JAZZ
$235.67+1.14%
as of close, Oct 2, 2026
☾ AH $235.67 +1.14%
Jazz Pharmaceuticals plc Common Stock (Ireland)Stock · Health CareNasdaq Composite 0.03%US Stock Market 0.02%Russell 3000 0.02%
JAZZ — Jazz Pharmaceuticals plc Common Stock (Ireland) price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeEEEE
100.0120.0140.0160.0180.0200.0220.0240.0260.0010.0M$235.67—20162019202120242026
2026-10-02
Price$235.67
MA20$236.77
MA50$187.94
Vol5.1M
Key stats
Price data
- Price
- $235.67
- Change YTD
- +38.63%
- Next earnings
- Nov 4, 2026
- Market cap
- 15.3B
- Enterprise value
- 17.5B
- Shares outstanding
- 64.9M
- 52W low
- $128.80
- 52W high
- $266.38
- From 52W high
- -11.53%
- From 52W low
- +82.97%
- 52W range
- 78%
- Beta
- 0.36
Volume
- Rel volume
- 0.65×
- 30D volume
- 979.3K
- 30D $ vol
- 239.6M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$775K
- Insider net 3M
- −$23.0M
- Insider net 1Y
- −$46.0M
Form 4 transactions by trade date, as filed; latest on file 2026-09-10.
Fundamentals
- Sales (ttm)
- 4.6B
- Sales/share
- $70.88
- EPS (ttm)
- $14.58
- FCF (ttm)
- 1.6B
- FCF/share
- $24.51
- Book value/share
- $73.97
- Net margin
- 20.45%
- ROE
- 19.59%
- ROA
- 8.49%
- Debt / equity
- 0.69×
- Current ratio
- 1.78
Growth (CAGR, ttm) · 10Y
- Sales
- +12.60%+6.93%+11.87%+12.65%
- Net income
- n/an/a+87.92%+10.05%
- FCF
- +25.81%+5.29%+16.11%+11.03%
- Shares
- +7.02%+0.93%+1.20%+0.70%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- n/an/a+72.67%+9.71%
- Sales/share
- +5.21%+5.95%+10.54%+11.86%
- FCF/share
- +17.56%+4.32%+14.73%+10.26%
- Book value/share
- +21.07%+9.82%+1.83%+9.53%
- Price
- +71.82%+22.65%+12.63%+6.85%
- Total return
- +71.82%+22.65%+12.63%+6.85%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 16.2×
- P/OI (ttm)
- 17.1×
- Fwd P/E
- 9.2×
- P/S (ttm)
- 3.3×
- P/B (mrq)
- 3.2×
- P/FCF (ttm)
- 9.6×
- EV/EBITDA (fy)
- 18.2×
- EV/Sales (ttm)
- 3.8×
- FCF yield (ttm)
- 10.40%
- Buyback yield (realized, 1y)
- -7.02%
- Shareholder yield (realized, 1y)
- -7.02%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/E
- 25th
- P/OI
- 54th
- P/S
- 54th
- P/B
- 75th
- P/FCF
- 47th
Bar = where today’s multiple sits in JAZZ’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-02
1D
+1.14%
5D
-0.96%
1M
-4.03%
3M
-3.20%
YTD
+38.63%
1Y
+71.76%
5Y
+81.33%
Recent filings
- Sep 238-K · Material definitive agreement; New financial obligation
- Sep 158-K · Regulation FD disclosure
- Sep 10Insider sale · Patil Neena M (EVP & Chief Legal Officer) sold 1,200 shares for $289K at $240.94 under a 10b5-1 plan
- Sep 8Insider sale · GALA RENEE D (President & CEO) sold 2,000 shares for $486K at $243.03 under a 10b5-1 plan
- Sep 1Insider sale · COZADD BRUCE C (Director) sold 6,000 shares for $1.5M at $250.13 under a 10b5-1 plan
Financial statements
Open full JAZZ financials →Loading financial statements…
Related Health Care
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| NVS | Novartis AG | -13.21% | -0.04% |
| NVO | Novo Nordisk A/S | -20.21% | -0.21% |
| SNY | Sanofi ADS | -10.23% | -1.84% |
| GSK | GSK plc American Depositary Shares (Each representing two Ordinary Shares) | -6.76% | -0.32% |
| NTRA | Natera Inc. | +26.20% | +0.46% |
| ARGX | argenx SE American Depositary Shares | -12.90% | -1.79% |
| TAK | Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | -3.09% | +0.00% |
| TEVA | Teva Pharmaceutical Industries Limited American Depositary Shares | +5.44% | +0.56% |
